Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday.
Information in Investors Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. … [+1064 chars]